Special Issue

Targeting Solid Tumors and the Microenvironment with Novel Immunotherapies

Message from the Guest Editors

It is very important to understand the mechanisms of tumorigenesis and surrounding tumor microenvironment in order to more efficiently target tumors. Novel therapeutic combination approaches and immunotherapies are needed to best target not only tumors but the surrounding microenvironment, as well. This goal of this Special Issue is to highlight novel immunotherapies against solid tumors such as oncolytic viruses, vaccines, dendritic vaccines, TCR mimics, neoantigens, personalized medicine approaches, epigenetic and genetic signaling, nanoparticle-based immunotherapies, NK cells, CAR-T cells, checkpoint inhibitors, and modulators of the microenvironment. In this Special Issue, original research articles and reviews are welcome. Research areas may include but are not limited to the following: personalized therapy, vaccines, oncolytic viruses, dendritic vaccines, monoclonal antibodies, bispecific antibodies, cell therapies, mechanisms of tumor resistance, and tumor microenvironment pathways.

Guest Editors

Dr. Vita Golubovskaya

- 1. Promab Biotechnologies, 2600 Hilltop Drive, Building B, C348, Richmond, CA 94803, USA
- Department of Medicine, University of Oklahoma Health Sciences Center, Andrews Academic Tower, 800 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA

Prof. Dr. Walter F. Bodmer

Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford OX3 9DS, UK

Deadline for manuscript submissions

closed (30 January 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/169340

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

